These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 25380674)

  • 21. The role of GSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: A review of the literature.
    Costemale-Lacoste JF; Guilloux JP; Gaillard R
    Encephale; 2016 Apr; 42(2):156-64. PubMed ID: 26995153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Free and nanoencapsulated curcumin suppress β-amyloid-induced cognitive impairments in rats: involvement of BDNF and Akt/GSK-3β signaling pathway.
    Hoppe JB; Coradini K; Frozza RL; Oliveira CM; Meneghetti AB; Bernardi A; Pires ES; Beck RC; Salbego CG
    Neurobiol Learn Mem; 2013 Nov; 106():134-44. PubMed ID: 23954730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glycogen synthase kinase 3beta and Alzheimer's disease: pathophysiological and therapeutic significance.
    Balaraman Y; Limaye AR; Levey AI; Srinivasan S
    Cell Mol Life Sci; 2006 Jun; 63(11):1226-35. PubMed ID: 16568235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GSK-3β Inhibition Affects Singing Behavior and Neurogenesis in Adult Songbirds.
    Aloni E; Shapira M; Eldar-Finkelman H; Barnea A
    Brain Behav Evol; 2015; 85(4):233-44. PubMed ID: 26065821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lithium blocks stress-induced changes in depressive-like behavior and hippocampal cell fate: the role of glycogen-synthase-kinase-3beta.
    Silva R; Mesquita AR; Bessa J; Sousa JC; Sotiropoulos I; Leão P; Almeida OF; Sousa N
    Neuroscience; 2008 Mar; 152(3):656-69. PubMed ID: 18291594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isorhynchophylline treatment improves the amyloid-β-induced cognitive impairment in rats via inhibition of neuronal apoptosis and tau protein hyperphosphorylation.
    Xian YF; Mao QQ; Wu JC; Su ZR; Chen JN; Lai XP; Ip SP; Lin ZX
    J Alzheimers Dis; 2014; 39(2):331-46. PubMed ID: 24164737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanisms and Therapeutic Implications of GSK-3 in Treating Neurodegeneration.
    Rippin I; Eldar-Finkelman H
    Cells; 2021 Jan; 10(2):. PubMed ID: 33572709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glycogen synthase kinase 3beta as a target for the therapy of shock and inflammation.
    Dugo L; Collin M; Thiemermann C
    Shock; 2007 Feb; 27(2):113-23. PubMed ID: 17224784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glycogen synthase kinase-3: a target for novel bipolar disorder treatments.
    Gould TD; Zarate CA; Manji HK
    J Clin Psychiatry; 2004 Jan; 65(1):10-21. PubMed ID: 14744163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and Imaging.
    Pandey MK; DeGrado TR
    Theranostics; 2016; 6(4):571-93. PubMed ID: 26941849
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glycogen synthase kinase--3β inhibitors suppress leukemia cell growth.
    Song EY; Palladinetti P; Klamer G; Ko KH; Lindeman R; O'Brien TA; Dolnikov A
    Exp Hematol; 2010 Oct; 38(10):908-921.e1. PubMed ID: 20540984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological inhibitors of glycogen synthase kinase 3.
    Meijer L; Flajolet M; Greengard P
    Trends Pharmacol Sci; 2004 Sep; 25(9):471-80. PubMed ID: 15559249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting glycogen synthase kinase-3 (GSK-3) in the treatment of Type 2 diabetes.
    MacAulay K; Woodgett JR
    Expert Opin Ther Targets; 2008 Oct; 12(10):1265-74. PubMed ID: 18781825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Berberine ameliorates β-amyloid pathology, gliosis, and cognitive impairment in an Alzheimer's disease transgenic mouse model.
    Durairajan SS; Liu LF; Lu JH; Chen LL; Yuan Q; Chung SK; Huang L; Li XS; Huang JD; Li M
    Neurobiol Aging; 2012 Dec; 33(12):2903-19. PubMed ID: 22459600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease.
    Hye A; Kerr F; Archer N; Foy C; Poppe M; Brown R; Hamilton G; Powell J; Anderton B; Lovestone S
    Neurosci Lett; 2005 Jan; 373(1):1-4. PubMed ID: 15555766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decreased glycogen synthase kinase-3 levels and activity contribute to Huntington's disease.
    Fernández-Nogales M; Hernández F; Miguez A; Alberch J; Ginés S; Pérez-Navarro E; Lucas JJ
    Hum Mol Genet; 2015 Sep; 24(17):5040-52. PubMed ID: 26082469
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic.
    Medina M; Castro A
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):533-43. PubMed ID: 18600569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Science Signaling Podcast for 15 November 2016: A new type of kinase inhibitor.
    Eldar-Finkelman H; VanHook AM
    Sci Signal; 2016 Nov; 9(454):c22. PubMed ID: 27902446
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of Isonicotinamides as Highly Selective, Brain Penetrable, and Orally Active Glycogen Synthase Kinase-3 Inhibitors.
    Luo G; Chen L; Burton CR; Xiao H; Sivaprakasam P; Krause CM; Cao Y; Liu N; Lippy J; Clarke WJ; Snow K; Raybon J; Arora V; Pokross M; Kish K; Lewis HA; Langley DR; Macor JE; Dubowchik GM
    J Med Chem; 2016 Feb; 59(3):1041-51. PubMed ID: 26751161
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of glycogen synthase kinase-3 enhances the differentiation and reduces the proliferation of adult human olfactory epithelium neural precursors.
    Manceur AP; Tseng M; Holowacz T; Witterick I; Weksberg R; McCurdy RD; Warsh JJ; Audet J
    Exp Cell Res; 2011 Sep; 317(15):2086-98. PubMed ID: 21708147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.